Dicot AB (DICOT.ST) stock: key figures, P/E, revenue and dividend
Health Care · Sweden
Dicot AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 0.00 SEK | 0.00 SEK |
| Operating income | -59.28 m SEK | -82.62 m SEK |
| EBIT | -57.69 m SEK | -80.23 m SEK |
| Net income | -57.70 m SEK | -80.24 m SEK |
| Diluted EPS – continuing operations | -0.03 SEK | -0.04 SEK |
Full history since 2021, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dicot AB
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
More stocks
- Advanced Optoelectronic Technology Inc (3437.TW)
- NanoTIM Co. Ltd. (417010.KQ)
- JOCOM HOLDINGS CORP. (JOCM)
- Axcen Photonics (6530.TWO)
- Ratchaphruek Hospital Public Company Limited (RPH.BK)
- Arla Plast AB (ARPL.ST)
- Embellence Group AB (EMBELL.ST)
- Eclatorq Technology Co. Ltd. (6855.TWO)
- Ambow Education Holding Ltd. (AMBO)
- Innotec Co., Ltd. (469610.KQ)
- Clipan Finance Indonesia Tbk (CFIN.JK)
- Wellpool Co Ltd (8424.TWO)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.